Company intelligence / Profile preview

Admedus Vaccines

Australia

Ownership: Private
Development stage: Other

Overview

DNA vaccine for HSV-2 showed 58% reduction in viral shedding and 52% reduction in outbreaks in Phase IIa interim results, but program discontinued after company name change in 2020.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccine
Industry: Biotech

Beyond the preview

Go deeper on Admedus Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Admedus Vaccines.

Explore the full profile